Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer.

Levy MJ, Alberts SR, Bamlet WR, Burch PA, Farnell MB, Gleeson FC, Haddock MG, Kendrick ML, Oberg AL, Petersen GM, Takahashi N, Chari ST.

Gastrointest Endosc. 2017 Jul;86(1):161-169. doi: 10.1016/j.gie.2016.11.014. Epub 2016 Nov 23.

2.

Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson.

Chaiteerakij R, Petersen GM, Bamlet WR, Chaffee KG, Zhen DB, Burch PA, Leof ER, Roberts LR, Oberg AL.

J Clin Oncol. 2016 Jun 1;34(16):1898-904. doi: 10.1200/JCO.2015.63.3511. Epub 2016 Apr 11.

3.

Risk factors for pancreatic neuroendocrine tumors: a clinic-based case-control study.

Halfdanarson TR, Bamlet WR, McWilliams RR, Hobday TJ, Burch PA, Rabe KG, Petersen GM.

Pancreas. 2014 Nov;43(8):1219-22. doi: 10.1097/MPA.0000000000000234.

4.

Impact of diabetes mellitus on clinical outcomes in patients undergoing surgical resection for pancreatic cancer: a retrospective, cohort study.

Hart PA, Law RJ, Frank RD, Bamlet WR, Burch PA, Petersen GM, Rabe KG, Chari ST.

Am J Gastroenterol. 2014 Sep;109(9):1484-92. doi: 10.1038/ajg.2014.193. Epub 2014 Jul 29.

5.

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.

Johnson DR, Kimmel DW, Burch PA, Cascino TL, Giannini C, Wu W, Buckner JC.

Neuro Oncol. 2011 May;13(5):530-5. doi: 10.1093/neuonc/nor044.

6.

The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection.

Yoon HH, Khan M, Shi Q, Cassivi SD, Wu TT, Quevedo JF, Burch PA, Sinicrope FA, Diasio RB.

Mayo Clin Proc. 2010 Dec;85(12):1080-9. doi: 10.4065/mcp.2010.0421.

7.

Obesity adversely affects survival in pancreatic cancer patients.

McWilliams RR, Matsumoto ME, Burch PA, Kim GP, Halfdanarson TR, de Andrade M, Reid-Lombardo K, Bamlet WR.

Cancer. 2010 Nov 1;116(21):5054-62. doi: 10.1002/cncr.25465.

8.
9.

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW.

Cancer. 2009 Aug 15;115(16):3670-9. doi: 10.1002/cncr.24429.

10.

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.

Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, Dipaola RS, Crawford ED.

J Clin Oncol. 2009 May 20;27(15):2450-6. doi: 10.1200/JCO.2008.19.9810. Epub 2009 Apr 20.

11.

Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases.

Molina JR, Quevedo JF, Furth AF, Richardson RL, Zincke H, Burch PA.

Cancer. 2007 Dec 1;110(11):2434-40.

12.

Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.

Southwest Oncology Group, Berry DL, Moinpour CM, Jiang CS, Ankerst DP, Petrylak DP, Vinson LV, Lara PN, Jones S, Taplin ME, Burch PA, Hussain MH, Crawford ED.

J Clin Oncol. 2006 Jun 20;24(18):2828-35.

PMID:
16782921
13.

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED.

J Natl Cancer Inst. 2006 Apr 19;98(8):516-21.

PMID:
16622120
14.

A phase I clinical and pharmacokinetic study of CS-682 administered orally in advanced malignant solid tumors.

Delaunoit T, Burch PA, Reid JM, Camoriano JK, Kobayash T, Braich TA, Kaur JS, Rubin J, Erlichman C.

Invest New Drugs. 2006 Jul;24(4):327-33.

PMID:
16502355
15.

Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial.

Burch PA, Mailliard JA, Hillman DW, Perez EA, Krook JE, Rowland KM, Veeder MH, Cannon MW, Ingle JN.

Am J Clin Oncol. 2005 Apr;28(2):195-200.

PMID:
15803016
16.

A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.

Dy GK, Suri A, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Atherton PJ, Hanson LJ, Burch PA, Rubin J, Erlichman C, Adjei AA.

Cancer Chemother Pharmacol. 2005 Jun;55(6):522-30. Epub 2005 Mar 8.

PMID:
15754203
17.

Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.

Galanis E, Burch PA, Richardson RL, Lewis B, Pitot HC, Frytak S, Spier C, Akporiaye ET, Peethambaram PP, Kaur JS, Okuno SH, Unni KK, Rubin J.

Cancer. 2004 Dec 1;101(11):2557-66.

18.

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED.

N Engl J Med. 2004 Oct 7;351(15):1513-20.

19.

Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial.

Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlović S.

Prostate. 2004 Aug 1;60(3):197-204.

PMID:
15176049
20.

A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma.

Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ.

Cancer. 2003 Mar 15;97(6):1442-6.

21.

Birt-Hogg-Dube syndrome: an autosomal dominant disorder with predisposition to cancers of the kidney, fibrofolliculomas, and focal cutaneous mucinosis.

Lindor NM, Hand J, Burch PA, Gibson LE.

Int J Dermatol. 2001 Oct;40(10):653-6. No abstract available.

PMID:
11737429
22.

Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.

Alberts SR, Erlichman C, Sloan J, Okuno SH, Burch PA, Rubin J, Pitot HC, Goldberg RM, Adjei AA, Atherton PJ, Kaufmann SH.

Ann Oncol. 2001 May;12(5):627-31.

PMID:
11432620
23.

A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors.

Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J.

Cancer. 2001 Apr 15;91(8):1543-8.

PMID:
11301403
24.

Phase II evaluation of continuous-infusion 5-fluorouracil, leucovorin, mitomycin-C, and oral dipyridamole in advanced measurable pancreatic cancer: a North Central Cancer Treatment Group Trial.

Burch PA, Ghosh C, Schroeder G, Allmer C, Woodhouse CL, Goldberg RM, Addo F, Bernath AM, Tschetter LK, Windschitl HE, Cobau CD.

Am J Clin Oncol. 2000 Oct;23(5):534-7.

PMID:
11039519
25.

Phase II study of paclitaxel and cisplatin for advanced urothelial cancer.

Burch PA, Richardson RL, Cha SS, Sargent DJ, Pitot HC 4th, Kaur JS, Camoriano JK.

J Urol. 2000 Nov;164(5):1538-42.

PMID:
11025699
26.

Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study.

Burch PA, Block M, Schroeder G, Kugler JW, Sargent DJ, Braich TA, Mailliard JA, Michalak JC, Hatfield AK, Wright K, Kuross SA.

Clin Cancer Res. 2000 Sep;6(9):3486-92.

27.

A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas.

Burch PA, Bernath AM, Cascino TL, Scheithauer BW, Novotny P, Nair S, Buckner JC, Pfeifle DM, Kugler JW, Tschetter LK.

Invest New Drugs. 2000 Aug;18(3):275-80.

PMID:
10958598
28.

Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.

Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Alberts SA, Schaaf LJ, Elfring G, Miller LL.

Clin Cancer Res. 2000 Jun;6(6):2236-44.

29.

Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer.

Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, Padley DJ, Peshwa MV, Pitot HC, Richardson RL, Smits BJ, Sopapan P, Strang G, Valone FH, Vuk-Pavlović S.

Clin Cancer Res. 2000 Jun;6(6):2175-82.

30.

Renal cell carcinoma metastatic to the pancreas: clinical and radiological features.

Ghavamian R, Klein KA, Stephens DH, Welch TJ, LeRoy AJ, Richardson RL, Burch PA, Zincke H.

Mayo Clin Proc. 2000 Jun;75(6):581-5.

PMID:
10852418
31.

Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma.

De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, Burgart L, Gores GJ.

Liver Transpl. 2000 May;6(3):309-16.

32.

Results of irradiation or chemoirradiation following resection of gastric adenocarcinoma.

Henning GT, Schild SE, Stafford SL, Donohue JH, Burch PA, Haddock MG, Trastek VF, Gunderson LL.

Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):589-98.

PMID:
10701738
33.

Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma.

Henning GT, Schild SE, Stafford SL, Donohue JH, Burch PA, Haddock MG, Gunderson LL.

Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):109-18.

PMID:
10656381
34.

North Central Cancer Treatment Group Phase II study of 5-fluorouracil and high-dose levamisole for gastric and gastroesophageal cancer using survival as the primary endpoint of efficacy.

Burch PA, Keppen MD, Schroeder G, Rubin J, Krook JE, Dalton RJ, Gerstner JB, Jancewicz MT, Ebbert LP.

Am J Clin Oncol. 1999 Oct;22(5):505-8.

PMID:
10521068
35.

Phase I study of 5-fluorouracil administered by protracted venous infusion, leucovorin, and pelvic radiation therapy.

Martenson JA, Shanahan TG, O'Connell MJ, Cobau CD, Schroeder G, Burch PA, Levitt R, Rowland KM Jr.

Cancer. 1999 Aug 15;86(4):710-4.

PMID:
10440700
36.

Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer.

Quella SK, Loprinzi CL, Sloan J, Novotny P, Perez EA, Burch PA, Antolak SJ Jr, Pisansky TM.

J Urol. 1999 Jul;162(1):98-102.

PMID:
10379749
37.

Phase II North Central Cancer Treatment Group study of 2-cholorodeoxyadenosine in patients with recurrent glioma.

Rajkumar SV, Burch PA, Nair S, Dinapoli RP, Scheithauer B, O'Fallon JR, Etzell PS, Leitch JM, Morton RF, Marks RS.

Am J Clin Oncol. 1999 Apr;22(2):168-71.

PMID:
10199452
38.

Prostate-specific antigen decline after withdrawal of low-dose megestrol acetate.

Burch PA, Loprinzi CL.

J Clin Oncol. 1999 Mar;17(3):1087-8. No abstract available.

PMID:
10071307
39.

Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial.

Witte RS, Manola J, Burch PA, Kuzel T, Weinshel EL, Loehrer PJ Sr.

Invest New Drugs. 1998;16(2):191-5.

PMID:
9848585
40.

A phase II study of high-dose cimetidine and the combination 5-fluorouracil, interferon alpha-2A, and leucovorin in advanced renal cell adenocarcinoma.

Creagan ET, Veeder MH, Suman VJ, Burch PA, Maples WJ, Schaefer PL, Pfeifle DM, Dalton RJ, Hatfield AK, Poon MA.

Am J Clin Oncol. 1998 Oct;21(5):475-8.

PMID:
9781603
41.

Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results.

Galanis E, Buckner JC, Burch PA, Schaefer PL, Dinapoli RP, Novotny PJ, Scheithauer BW, Rowland KM, Vukov AM, Mailliard JA, Morton RF.

J Clin Oncol. 1998 Sep;16(9):2953-8.

PMID:
9738563
42.

Sarcoidosis and testicular carcinoma.

Rayson D, Burch PA, Richardson RL.

Cancer. 1998 Jul 15;83(2):337-43.

PMID:
9669817
43.

Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma.

Buckner JC, Burch PA, Cascino TL, O'Fallon JR, Scheithauer BW.

J Neurooncol. 1998 Jan;36(1):65-70.

PMID:
9525827
44.

Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.

Rajkumar SV, Buckner JC, Schomberg PJ, Cascino TL, Burch PA, Dinapoli RP.

Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):297-302.

PMID:
9457812
45.

Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.

Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM, Suman VJ.

Clin Cancer Res. 1997 Jul;3(7):1093-100.

46.

Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7.

Rubin J, Galanis E, Pitot HC, Richardson RL, Burch PA, Charboneau JW, Reading CC, Lewis BD, Stahl S, Akporiaye ET, Harris DT.

Gene Ther. 1997 May;4(5):419-25.

47.

Pilot study of continuous-infusion 5-fluorouracil, oral leucovorin, and upper-abdominal radiation therapy in patients with locally advanced residual or recurrent upper gastrointestinal or extrapelvic colon cancer.

Martenson JA, Swaminathan R, Burch PA, Santala RG, Schroeder G, Pitot HC, Wright K, Kugler JW, Stella PJ, Garton GR.

Int J Radiat Oncol Biol Phys. 1997 Feb 1;37(3):615-8.

PMID:
9112460
48.

Phase II trials of 5-fluorouracil and leucovorin in patients with metastatic gastric or pancreatic carcinoma.

Rubin J, Gallagher JG, Schroeder G, Schutt AJ, Dalton RJ, Kugler JW, Morton RF, Mailliard JA, Burch PA.

Cancer. 1996 Nov 1;78(9):1888-91.

PMID:
8909307
49.

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma.

Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL.

Cancer. 1995 Jul 1;76(1):96-100.

PMID:
8630883
50.

The role of irradiation as a component of combined modality treatment for gastric cancer.

Gunderson LL, Burch PA, Donohue JH.

J Infus Chemother. 1995 Summer;5(3):117-24. Review.

PMID:
8528968

Supplemental Content

Loading ...
Support Center